T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitis
人复发性扁桃体炎中滤泡辅助性 T (Tfh) CD4 T 细胞、生发中心和抗体反应功能障碍
基本信息
- 批准号:10366647
- 负责人:
- 金额:$ 500.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-11 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:Antibody ResponseAntibody-mediated protectionAntigensAntiviral AgentsB-LymphocytesBacteriaBacterial InfectionsBiologyBiopsyBloodCD4 Positive T LymphocytesCellsCellular biologyCharacteristicsChildChildhoodComplexDataDiseaseEffector CellExhibitsFine needle aspiration biopsyFunctional disorderGenerationsHelper-Inducer T-LymphocyteHeterogeneityHumanHuman Herpesvirus 4Humoral ImmunitiesImmune responseImmunityImmunizationIndividualInfectionInterleukin-9InterventionLinkLungLymphoid TissueMHC Class II GenesMedicalMemoryMolecularNewborn InfantPathologicPertussisPertussis VaccinePhenotypePlayProcessPropertyProviderRecurrenceRegulatory T-LymphocyteReportingRoleSourceStreptococcus pyogenesStructure of germinal center of lymph nodeT cell responseTechniquesTeenagersTestingTissuesTonsilTonsillectomyTonsillitisTransforming Growth Factor betaVaccinatedVaccinationVaccinesVirusVirus Diseasesadaptive immune responsecohortcost effectivecytokinecytotoxicimprintin vivoindividual responseinfancyinnovationlymph nodesmemory CD4 T lymphocytenovelpathogenpolarized cellresponsesingle-cell RNA sequencingtranscription factorvaccine developmentvaccine response
项目摘要
PROJECT SUMMARY
Overall Component
Vaccines are one of the most cost effective and extraordinarily successful medical interventions. Most of those
vaccines depend on CD4 T+ cells and their help to B cells. Our understanding of in vivo, specific human CD4+ T
cell responses to pathogens remains hazy, due to the complexity of the biology, the rarity of the cells, relatively
inaccessible tissue localization, and technical challenges of identifying specific CD4+ T cells. Therefore, our
approach to this serious problem has been to develop multiple new techniques to study human CD4+ T cells
over the past several years. While CD4+ T cell-dependent antibody responses have been the source of protection
for most licensed vaccines (Project 1), there is a very good argument to be made that many of the diseases for
which we do not have successful vaccines require adaptive immune responses beyond antibodies for protection
(Projects 2 and 3). The three Projects proposed here vigorously pursue an understanding of the mechanisms
regulating human anti-pathogen CD4+ T cells, linked by new experimental approaches.
项目总结
整体组件
疫苗是最具成本效益和非常成功的医疗干预措施之一。其中的大多数
疫苗依赖于CD4T+细胞及其对B细胞的帮助。我们对体内、特异性人类CD4+T细胞的理解
细胞对病原体的反应仍然是模糊的,由于生物学的复杂性,细胞的稀有性,相对
难以接近的组织定位,以及识别特定CD4+T细胞的技术挑战。因此,我们的
解决这一严重问题的方法一直是开发多种新技术来研究人类CD4+T细胞
在过去的几年里。虽然依赖于CD4+T细胞的抗体反应一直是保护性的来源
对于大多数获得许可的疫苗(项目1),有一个非常好的论点,即许多疾病
我们没有成功的疫苗需要适应性免疫反应,而不是抗体来保护
(项目2和项目3)。这里提出的三个项目积极寻求对机制的理解
通过新的实验方法调节人类抗病原体CD4+T细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shane P Crotty其他文献
Shane P Crotty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shane P Crotty', 18)}}的其他基金
Immune engineering of optimized sequential immunization strategies for HIV vaccines
HIV疫苗序贯免疫策略优化的免疫工程
- 批准号:
10588202 - 财政年份:2021
- 资助金额:
$ 500.7万 - 项目类别:
Immune engineering of optimized sequential immunization strategies for HIV vaccines
HIV疫苗序贯免疫策略优化的免疫工程
- 批准号:
10383728 - 财政年份:2021
- 资助金额:
$ 500.7万 - 项目类别:
T follicular helper (Tfh) CD4+ T cell, germinal center, and antibody response dysfunction in human recurrent tonsillitis
人复发性扁桃体炎中滤泡辅助性 T (Tfh) CD4 T 细胞、生发中心和抗体反应功能障碍
- 批准号:
10304742 - 财政年份:2020
- 资助金额:
$ 500.7万 - 项目类别:
Bcl6 and transcription factors that program TFH differentiation and function
Bcl6 和转录因子编程 TFH 分化和功能
- 批准号:
10224892 - 财政年份:2020
- 资助金额:
$ 500.7万 - 项目类别:
Bcl6 and transcription factors that program TFH differentiation and function
Bcl6 和转录因子编程 TFH 分化和功能
- 批准号:
10683269 - 财政年份:2020
- 资助金额:
$ 500.7万 - 项目类别:
Transcription factor regulation of CD4 and CD8 T cell effector and memory differentiation and function
CD4 和 CD8 T 细胞效应及记忆分化和功能的转录因子调节
- 批准号:
10024583 - 财政年份:2020
- 资助金额:
$ 500.7万 - 项目类别:
相似海外基金
Durable Antibody Mediated Protection Against HIV
持久的抗体介导的艾滋病毒保护
- 批准号:
9141189 - 财政年份:2016
- 资助金额:
$ 500.7万 - 项目类别:
Project 2- Mechanism of How Vaccine-Elicited CD4+ T Cells Attenuate Antibody Mediated Protection
项目 2 - 疫苗诱导的 CD4 T 细胞如何减弱抗体介导的保护的机制
- 批准号:
9141193 - 财政年份:2016
- 资助金额:
$ 500.7万 - 项目类别:
Antibody-mediated protection against cell-associated HIV
抗体介导的针对细胞相关 HIV 的保护
- 批准号:
300439 - 财政年份:2013
- 资助金额:
$ 500.7万 - 项目类别:
Fellowship Programs
Role of Fc Receptor Polymorphisms in Antibody-Mediated Protection
Fc 受体多态性在抗体介导的保护中的作用
- 批准号:
8410766 - 财政年份:2012
- 资助金额:
$ 500.7万 - 项目类别:
Cell Death and Antibody-Mediated Protection from Autoimmunity
细胞死亡和抗体介导的自身免疫保护
- 批准号:
8264838 - 财政年份:2011
- 资助金额:
$ 500.7万 - 项目类别:
Cell Death and Antibody-Mediated Protection from Autoimmunity
细胞死亡和抗体介导的自身免疫保护
- 批准号:
7892627 - 财政年份:2009
- 资助金额:
$ 500.7万 - 项目类别:
Identifying epitopes that induce antibody mediated protection against foot-and-mouth disease using reverse genetics
使用反向遗传学识别诱导抗体介导的口蹄疫保护的表位
- 批准号:
BB/F009186/1 - 财政年份:2009
- 资助金额:
$ 500.7万 - 项目类别:
Research Grant
Mechanisms of non-neutralizing antibody-mediated protection from influenza virus
非中和抗体介导的流感病毒保护机制
- 批准号:
7915053 - 财政年份:2009
- 资助金额:
$ 500.7万 - 项目类别:
Mechanisms of non-neutralizing antibody-mediated protection from influenza virus
非中和抗体介导的流感病毒保护机制
- 批准号:
7643166 - 财政年份:2008
- 资助金额:
$ 500.7万 - 项目类别:
Mechanisms of non-neutralizing antibody-mediated protection from influenza virus
非中和抗体介导的流感病毒保护机制
- 批准号:
7511491 - 财政年份:2008
- 资助金额:
$ 500.7万 - 项目类别: